---
title: "Haitong International gives DUALITYBIO a target price of 457.74 yuan and a rating of \"Outperform the Market\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282279405.md"
description: "Haitong International released a research report on DUALITYBIO, adjusting the target price to RMB 457.74, with a rating of \"Outperform the Market.\" The report pointed out that DUALITYBIO's revenue last year was RMB 1.85 billion, a year-on-year decrease of 5%, mainly affected by revenue from licensing and collaboration agreements. R&D expenses remained flat, with a net loss attributable to the parent company of RMB 2.6 billion for the year. It is expected that the loss will decrease to RMB 1.05 billion in 2024, and the revenue forecasts for this year and next year have been adjusted to RMB 1.8 billion and RMB 1.7 billion, respectively"
datetime: "2026-04-10T02:24:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282279405.md)
  - [en](https://longbridge.com/en/news/282279405.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282279405.md)
---

# Haitong International gives DUALITYBIO a target price of 457.74 yuan and a rating of "Outperform the Market"

Haitong International published a research report stating that DUALITYBIO (09606.HK) achieved revenue of RMB 1.85 billion last year, a year-on-year decrease of 5%, mainly from licensing and collaboration agreement income. Research and development expenses were RMB 840 million, basically flat year-on-year. The net loss attributable to the parent company for the year was RMB 2.6 billion, compared to a loss of RMB 1.05 billion in the same period of 2024, mainly affected by the one-time impact of the fair value change of financial liabilities from the company's listing in the Hong Kong market and the conversion of preferred shares.

The firm adjusted its forecast for potential future sales revenue from BioNTech based on the progress of DUALITYBIO's clinical pipeline, revising this year's and next year's revenue forecasts to RMB 1.8 billion and RMB 1.7 billion respectively (originally expected to be RMB 1 billion in 2026), and net loss forecasts to RMB 370 million and RMB 170 million (originally expected net loss of approximately RMB 980 million in 2026).

The firm adjusted its target price to RMB 457.74, maintaining an "outperform" rating

### Related Stocks

- [09606.HK](https://longbridge.com/en/quote/09606.HK.md)

## Related News & Research

- [Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement](https://longbridge.com/en/news/286834766.md)
- [Hong Kong’s 2nd richest billionaires Peter and Martin Lee’s Henderson Land secures city’s first biodiversity loan](https://longbridge.com/en/news/286508532.md)
- [13:19 ETHyosung TNC Marks a Major Step in its Integrated Bio-Spandex Platform at Global Fashion Summit 2026](https://longbridge.com/en/news/286296991.md)
- [Covia: Stewardship in Action Across Our Sites](https://longbridge.com/en/news/286428598.md)
- [India soymeal exports to fall to four-year low on rising prices](https://longbridge.com/en/news/286881552.md)